Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
24.18
+1.62 (7.18%)
At close: Jul 30, 2026, 4:00 PM EDT
24.31
+0.13 (0.54%)
After-hours: Jul 30, 2026, 5:01 PM EDT
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $71.55M in the quarter ending June 30, 2026, with 21.53% growth. This brings the company's revenue in the last twelve months to $308.08M, up 50.13% year-over-year. In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth.
Revenue (ttm)
$308.08M
Revenue Growth
+50.13%
P/S Ratio
11.86
Revenue / Employee
$493,720
Employees
624
Market Cap
3.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.98M | 98.02M | 54.77% |
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 766.30M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
ADPT News
- 8 hours ago - Adaptive Biotechnologies price target raised to $27 from $25 at JPMorgan - TheFly
- 8 hours ago - Adaptive Biotechnologies price target raised to $22 from $20 at Morgan Stanley - TheFly
- 9 hours ago - Adaptive Biotechnologies price target raised to $25 from $24 at BTIG - TheFly
- 9 hours ago - Adaptive Biotechnologies price target raised to $28 from $25 at TD Cowen - TheFly
- 10 hours ago - Adaptive Biotechnologies price target raised to $25 from $22 at Guggenheim - TheFly
- 1 day ago - Adaptive Biotechnologies reports Q2 EPS (25c), consensus (13c) - TheFly
- 1 day ago - Adaptive Biotechnologies sees FY26 revenue $268M-$278M from MRD business - TheFly
- 1 day ago - Adaptive Biotechnologies Earnings Call Transcript: Q2 2026 - Transcripts